Lake Street analyst Thomas Flaten maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and adjusts the target price from $34 to $40.
According to TipRanks data, the analyst has a success rate of 40.8% and a total average return of 3.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences has reported another quarter of robust financial performance, surpassing expectations and demonstrating its second successive quarter of GAAP profitability. The positive risk/reward profile of the stock is evident, and there is a strong possibility that reimbursement for the company's squamous cell carcinoma test may be extended beyond the current period. This is based on the fact that the company has been receiving payments for over two and a half years and has effectively gathered further evidence and data that could justify ongoing Medicare reimbursement.
The firm indicated that Castle Biosciences delivered a solid third quarter, with revenues meeting expectations and showing promising operational expenditure leverage. The company saw overall volume growth, although dermatology volumes fell short of estimates, which was attributed to seasonal factors. Furthermore, the TissueCypher product continued to exhibit strong momentum.
The company's expansion in test volumes, particularly in IDgenetix and TissueCypher, has been noted as contributing to robust quarterly results and an upward revision in revenue guidance.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Lake Street分析师Thomas Flaten维持$Castle Biosciences (CSTL.US)$买入评级，并将目标价从34美元上调至40美元。
根据TipRanks数据显示，该分析师近一年总胜率为40.8%，总平均回报率为3.2%。
此外，综合报道，$Castle Biosciences (CSTL.US)$近期主要分析师观点如下：
Castle Biosciences报告了又一个季度的强劲财务业绩，超出了预期，并连续第二个季度实现了GAAP的盈利能力。该股的积极风险/回报状况显而易见，该公司鳞状细胞癌测试的报销很有可能延长到本期以后。这是基于这样一个事实，即该公司已经收到付款超过两年半，并且有效地收集了进一步的证据和数据，可以证明持续的医疗保险报销是合理的。
该公司表示，Castle Biosciences实现了稳健的第三季度业绩，收入符合预期，运营支出杠杆率表现出良好的前景。该公司的整体销量有所增长，尽管皮肤科产量低于预期，这归因于季节性因素。此外，TissueCypher产品继续表现出强劲的势头。
该公司测试量的扩大，尤其是IDGenetix和TissueCypher的测试量的扩大，被认为促进了强劲的季度业绩和收入指引的上调。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
